Brown, Lisle/Cummings’s AbbVie ABBV Stock Holding History

Brown, Lisle/Cummings’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.28M	Buy	28,857 +278	+1%	+$61.7K	1.57%	11
2025 Q4	$6.53M	Buy	28,579 +534	+2%	+$122K	1.61%	11
2025 Q3	$6.49M	Hold	28,045	–	–	1.67%	11
2025 Q2	$5.21M	Sell	28,045 -174	-0.6%	-$32.3K	1.39%	16
2025 Q1	$5.91M	Buy	28,219 +181	+0.6%	+$35.2K	1.71%	10
2024 Q4	$4.98M	Sell	28,038 -53	-0.2%	-$9.74K	1.49%	12
2024 Q3	$5.55M	Buy	28,091 +1,450	+5%	+$271K	1.69%	11
2024 Q2	$4.57M	Buy	26,641 +1,124	+4%	+$186K	1.49%	13
2024 Q1	$4.65M	Hold	25,517	–	–	1.58%	12
2023 Q4	$3.95M	Buy	25,517 +4,025	+19%	+$587K	1.47%	12
2023 Q3	$3.2M	Buy	21,492 +425	+2%	+$62.4K	1.45%	17
2023 Q2	$2.84M	Buy	21,067 +1,125	+6%	+$165K	1.27%	20
2023 Q1	$3.18M	Sell	19,942 -26	-0.1%	-$3.98K	1.61%	12
2022 Q4	$3.23M	Sell	19,968 -953	-5%	-$146K	1.73%	10
2022 Q3	$2.81M	Hold	20,921	–	–	1.64%	13
2022 Q2	$3.2M	Sell	20,921 -7	-0%	-$1.07K	1.77%	13
2022 Q1	$3.39M	Buy	20,928 +65	+0.3%	+$9.44K	1.63%	13
2021 Q4	$2.82M	Buy	+20,863	New	+$2.46M	1.41%	15

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Brown, Lisle/Cummings's ABBV Position: Q1 2026 in Review

Brown, Lisle/Cummings increased its AbbVie (ABBV) stake by 0.97% in Q1 2026, buying an estimated $61.7K and bringing the position to 28,857 shares worth $6.28M. The position accounts for 1.57% of the portfolio, ranked #11.

Brown, Lisle/Cummings first reported a position in ABBV in Q4 2021 and has held it in 18 quarters since. The position peaked at $6.53M in Q4 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Brown, Lisle/Cummings held 28,857 shares of AbbVie worth $6.28M as of Q1 2026.
Brown, Lisle/Cummings bought 278 AbbVie shares in Q1 2026, an estimated $61.7K.
AbbVie made up 1.57% of Brown, Lisle/Cummings's portfolio in Q1 2026, its #11 holding.
Brown, Lisle/Cummings first reported a position in AbbVie in Q4 2021 and has held it in 18 quarters since.
Brown, Lisle/Cummings's AbbVie position peaked at $6.53M in Q4 2025.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q1 2026, filed 20 Apr 2026.